MedPath

Effect of a Botanical Ingredient in Healthy Subjects With Anxiety and Poor Sleep Quality

Not Applicable
Completed
Conditions
Poor Quality Sleep
Interventions
Dietary Supplement: Control group
Dietary Supplement: Botanical ingredient
Registration Number
NCT06154629
Lead Sponsor
Universidad Católica San Antonio de Murcia
Brief Summary

Randomized, controlled, double-blind, single-center clinical trial with two parallel arms depending on the product consumed (experimental product and placebo product) to analyze the efficacy of a botanical extract in reducing anxiety and improving sleep quality.

Detailed Description

Subjects who meet the selection criteria will be randomly assigned to each of the study groups (investigational product dose or placebo, depending on the group to which they have been assigned).

The product to be consumed is a botanical extract. Participants will consume the product for 90 days. They should consume one capsule one hour before going to sleep.

They will make a total of five visits to the research laboratory and the tests preestablished in the protocol will be performed. Subsequently, a statistical analysis will be performed with the variables measured in the study to obtain the results.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
79
Inclusion Criteria
  • Healthy adults.
  • Moderate levels of anxiety by STAI.
  • Low sleep quality by PSQI.
  • Volunteers able to understand the clinical study and willing to comply with its procedures and requirements.
Exclusion Criteria
  • Serious or terminal illness.
  • Subjects with body mass index above 32 kg/m2. Pregnant or lactating women.
  • Participation in another study involving blood draws or dietary intervention.
  • Organic dementias such as Alzheimer's, Huntington's disease, Parkinson's and senile dementia.
  • Hypersensitivity to the components of the formula.
  • Use of medications that alter cognitive functions or sleep, such as barbiturates, anticonvulsants, benzodiazepines, antidepressants, neuroleptics, alcohol and illicit drugs.
  • Subjects with known allergy to some of the study components.
  • Inability to understand the informed consent.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Control GroupControl groupConsumption for 90 days. Subjects should consume one capsule one hour before going to sleep
Botanical ingredientBotanical ingredientConsumption for 90 days. Subjects should consume one capsule one hour before going to sleep
Primary Outcome Measures
NameTimeMethod
Variation in sleep quality from baseline at 12 weeks.The evolution of sleep quality after consumption during 12 weeks will be measured.

Visual analog scale from 0 to 10. The higher the value, the more quality.

Secondary Outcome Measures
NameTimeMethod
Anxiety questionnaireDay 1, at 12 weeks later

Test STAI, to measure the level of anxiety of the subjects

Change in Sleep Quality from baseline at 12 weeksSleep quality will be measured with a daily scale, from baseline to 12 weeks.

Visual analog scale from 0 to 10. The higher the value, the more quality.

MelatonineIt will be measured twice, once at baseline or at the end of the study after 12 weeks of use

It is measured with a blood sample in the early evening.

Liver safety variablesIt will be measured twice, once at baseline or at the end of the study after 12 weeks.

It is a blood test that measures the presence of some enzymes, proteins and bilirubin in the blood, with the aim of determining if there is any alteration in the liver. Enzyme GPT, GOT, Gamma GT, LDH, alkaline phosphatase and bilirubin (UI/L)

Adverse eventsAt 12 weeks after consumption

It will be evaluated at each of the visits.

Sleep qualityIt will be measured twice, once at baseline or at the end of the study after 12 weeks of use

Measured by Pittsburgh test

Sleep efficiencyIt will be measured during 4 working days and one weekend day, before starting the consumption of the product and before the end of consumption (90 days).

Measured by accelerometry, with Actigraph wGT3X-BT

Perceived stress scaleDay 1, at 12 weeks later

Scale Remor, 2001. Test to measure the level of stress of the subjects

CortisolIt will be measured twice, once at baseline or at the end of the study after 12 weeks of use

Measured with blood sample first thing in the morning.

Body compositionThe test will be measured at baseline and after 12 weeks of consumption.

It is a control variable. Measured by bioimpedance

Physical activity controlIt will be measured during 4 working days and one weekend day, before starting the consumption of the product and before the end of consumption (90 days).

It is a control variable. Measured by Actigraph wGT3X-BT

Trial Locations

Locations (1)

Catholic University of Murcia

🇪🇸

Murcia, Spain

© Copyright 2025. All Rights Reserved by MedPath